Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace As of June 29, there were 13 vaccines against COVID-19 in human clinical trials. According to the World Health Organization, as of June 22, there were more than 140 vaccines in development. The furthest ahead are […]
The Coalition for Epidemic Preparedness Innovation (CEPI) plans to have two or three manufacturing plants for each vaccine, James Robinson, a longtime biopharma executive leading CEPI’S vast manufacturing push, said in an interview.
Gilead Sciences Inc. expects supply of the potential COVID-19 drug remdesivir to exceed two million courses by year-end, more than double the company’s previous target of 1 million.
Emergent BioSolutions signed an $87 million deal to make AstraZeneca’s experimental COVID-19 vaccine in the United States.
AstraZeneca announced plans to manufacture 2 billion doses of the University of Oxford’s COVID-19 vaccine, AZD122.
Maryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
Gilead Sciences Inc., maker of the closely watched experimental coronavirus drug remdesivir, said the company will work with international partners to expand production of the potential COVID-19 treatment.
U.S. President Donald Trump said the United States plans to accelerate the development of a coronavirus vaccine, an effort that has been dubbed “Operation Warp Speed.”
Less than one month after Johnson & Johnson identified a lead vaccine candidate against COVID-19, the life sciences giant announced an agreement with Emergent BioSolutions to support the manufacturing needs for the potential medication.
In a competitive market, brands rely on their reputations to give them an edge. However, these reputations are built on perceptions — and because it’s up to consumers to develop their own perceptions, brands may feel as though they have less control in developing lasting loyalty. This is especially true in the pharmaceutical industry due to where pharmaceutical manufacturers reside within healthcare’s value chain. In the patient-doctor relationship, pharmaceutical companies are the left-out third wheel.